Hearing loss is one of the most modifiable risk factors for dementia identified to date, yet a persistent question has remained unanswered: does simply wearing a hearing aid matter, or does it only matter when the device actually works? This large multinational analysis resolves that ambiguity in a clinically meaningful way, with implications for how hearing rehabilitation is prescribed, monitored, and prioritized globally.
Drawing on harmonized longitudinal data from seven major aging cohorts — spanning China, South Korea, Europe, the United States, Ireland, and Mexico — researchers tracked 61,089 hearing-impaired adults aged 55 and older over an average of 6.5 years, capturing 8,911 dementia events. Using inverse probability of treatment weighting to reduce confounding, Cox proportional hazard models revealed that hearing aid use overall was associated with a 9% reduction in dementia risk (HR = 0.91). Critically, this benefit was driven entirely by participants who reported genuine hearing improvement: their hazard ratio dropped to 0.86, a 14% risk reduction. Those who used hearing aids but reported poor hearing improvement showed no protective signal (HR = 0.98). Notably, the association was substantially stronger in middle-income countries (HR = 0.76) and among adults under 70, women, unmarried individuals, and those with lower educational attainment.
This finding sharpens a debate that previous observational work — including the 2023 ACHIEVE trial — left somewhat unresolved. Where ACHIEVE found cognitive benefits primarily in higher-risk subgroups over three years, this pooled analysis across 33 countries suggests that device efficacy, not mere use, is the active ingredient. The biological plausibility is strong: effective amplification may preserve auditory cortex engagement, reduce cognitive load from effortful listening, and maintain social connectivity — all pathways implicated in dementia pathogenesis. Key limitations include the observational design, self-reported hearing improvement measures, and heterogeneity across cohorts. Still, the scale, geographic breadth, and methodological rigor place this among the more persuasive epidemiological contributions to the hearing-dementia literature. For public health, the takeaway is structural: dispensing a device is insufficient without ensuring it delivers functional benefit.